Hims & Hers Health (HIMS) Stock Price, News & Analysis

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hims & Hers Health in the last twelve months. There are currently 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HIMS shares.
View HIMS analyst ratings or view top-rated stocks.

13 equities research analysts have issued 12 month target prices for Hims & Hers Health's stock. Their HIMS share price targets range from $10.00 to $20.00. On average, they anticipate the company's share price to reach $14.85 in the next twelve months. This suggests a possible upside of 20.3% from the stock's current price.
View analysts price targets for HIMS or view top-rated stocks among Wall Street analysts.

Hims & Hers Health's stock was trading at $8.90 on January 1st, 2024. Since then, HIMS stock has increased by 38.7% and is now trading at $12.34.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our HIMS earnings forecast.

Hims & Hers Health will be holding an earnings conference call on Monday, May 6th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

Hims & Hers Health, Inc. (NYSE:HIMS) posted its quarterly earnings results on Monday, February, 26th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.02) by $0.03. The business earned $246.60 million during the quarter, compared to analysts' expectations of $245.84 million. Hims & Hers Health had a negative net margin of 2.70% and a negative trailing twelve-month return on equity of 7.21%. The firm's quarterly revenue was up 47.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.05) EPS.

ETFs with the largest weight of Hims & Hers Health (NYSE:HIMS) stock in their portfolio include Amplify Online Retail ETF (IBUY), SPDR S&P Health Care Services ETF (XHS), Global X Telemedicine & Digital Health ETF (EDOC), iShares Virtual Work and Life Multisector ETF (IWFH), Fidelity Digital Health ETF (FDHT), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and Global X Millennial Consumer ETF (MILN).

Hims & Hers Health updated its first quarter 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $267.0 million-$272.0 million, compared to the consensus revenue estimate of $251.3 million.

Hims & Hers Health's stock is owned by many different retail and institutional investors. Top institutional shareholders include State of Michigan Retirement System (0.08%), Cullinan Associates Inc. (0.03%), Los Angeles Capital Management LLC (0.01%), Counterpoint Mutual Funds LLC (0.01%), Fragasso Group Inc. (0.01%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Alex Bard, Andrew Dudum, David B Wells, David B Wells, Irene Becklund, Jack Abraham, Jules A Maltz, Lynne Chou O'keefe, Melissa Baird, Oluyemi Okupe, Patrick Harrison Carroll, Soleil Boughton and Spencer Lee.
View institutional ownership trends.

Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.